|Year : 2020 | Volume
| Issue : 2 | Page : 91-101
Ayurveda interpretation, diagnostic, and probable management of COVID-19 pandemic
Department of Panchakarma, Faculty of Ayurvedic Science, Jayoti Vidyapeeth Women’s University, Jaipur, Rajasthan, India
|Date of Submission||17-Jun-2020|
|Date of Decision||11-Jul-2020|
|Date of Acceptance||14-Jul-2020|
|Date of Web Publication||07-Sep-2020|
Dr. Sanjay Kumar
Department of Panchakarma, Faculty of Ayurvedic Science, Jayoti Vidyapeeth Women’s University, Jaipur, Rajasthan.
Source of Support: None, Conflict of Interest: None
Viral infections play a significant role in human illnesses. In late December 2019, a previously unidentified coronavirus, named as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 by ICTV on February 11, 2020), also named as 2019 novel coronavirus, originated from Wuhan, China, and caused outbreak in many countries. Presently, despite the advancement made in immunization and drug development, this virus lacks preventive vaccines and effective antiviral remedies. Thus, identification of specific antiviral medicine is of critical importance. However, classical Ayurveda preparations may play an excellent role in the management of this outbreak. Ayurveda has a unique method of approaching the newly detected disease. Rather than focusing on the microbial etiology, Ayurveda embraces a holistic technique for elaborating the details of the disease at hand. In this paper, we summarize the interpretation, diagnosis, treatment principles, and medicines described in different texts of Ayurveda to treat viral infections.
Keywords: Ayurveda, COVID-19, Infectious disease, Krimi, Panchakarma, pandemic
|How to cite this article:|
Kumar S. Ayurveda interpretation, diagnostic, and probable management of COVID-19 pandemic. J Indian Sys Medicine 2020;8:91-101
| Introduction|| |
A number of viral infections are responsible for human pathogeneses comprising pandemic diseases. Rapid urbanization and increased global travel cause pandemic outbreaks, and re-emerging viruses create a serious threat to social health.,, Currently, a number of viruses remain without actual immunization, and a few antiviral medicines are licensed for clinical practice. The condition is further exacerbated by the latent development of drug-resistant mutants, especially when using viral enzyme-specific inhibitors, which significantly obstructs drug efficacy.,,, Thus, there is a crucial need to develop specific antiviral drugs that are very effective and cost-effective in the treatment and control of viral infection. Ayurveda medicines and Panchakarma may provide an effective treatment for COVID-19 outbreak. In this paper, a summary of several Ayurveda preparations and herbal medicines against this coronavirus has been reported.
In December 2019, an epidemic of an unknown pneumonia characterized by fever, dry cough, fatigue, and infrequent gastrointestinal symptoms happened in a seafood market in Wuhan, Hubei, China.,, This pandemic emerged from China and has rapidly spread to most countries in the world. It was confirmed as a pandemic by the WHO on March 11, 2020, as it has confirmed its presence in all continents except Antarctica.,,,
Coronavirus is an enveloped, positive-sense, single-stranded RNA (ss-RNA) virus belonging to the Orthocoronavirinae subfamily of Coronaviridae family, with “crown-like” spikes on their surface. The precise source, location, and natural reservoir of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) remain uncertain, although it is believed that the virus is zoonotic, and bats may be the culprits because of the sequence identity to bat-CoV,, Initially, SARS-CoV-2 eruption was reported as limited person-to-person transmission, and a contaminated source from infected animals in the wet market may have been the common origin. But more and more evidences came out, with clusters of outbreaks among families confirming the possibility of person-to-person transmission.,,,,,,
| Symptoms of COVID-19|| |
The mean incubation period of COVID-19 is 5.2 days (95% confidence interval, 4.1–7.0). The symptoms begin with non-specific syndromes, comprising fever, dry cough, body pain, and fatigue. The symptoms may appear 2–14 days after exposure to the virus:
shortness of breath or difficulty in breathing
repeated shaking with chills
loss of taste or smell
These symptoms may become more severe in some people:
confusion or inability to arouse
persistent pain in the chest
bluish lips and/or face
The most serious complication of COVID-19 is a type of pneumonia called the novel coronavirus-infected pneumonia (NCIP). So far, NCIP is the only complication specifically linked to the 2019 coronavirus. Researchers have seen the following complications in people who developed COVID-19:
acute respiratory distress syndrome (ARDS)
irregular heart rate (arrhythmia)
severe muscle pain (myalgia)
heart damage or heart attack
Commonest signs and symptoms are fever (83–98%), cough (76–82%), and shortness of breath (31–55%). There were about 15% with fever, cough, and short of breath. These symptoms are usually mild and gradually worsen. Approximately 80% of COVID-19 cases showing mild symptoms require only primary medical treatment. In rest of the 20% cases, 15% need emergency medical attention at secondary healthcare hospitals and 5% critical cases need an intensive care and a transfer to tertiary healthcare centers equipped with an ICU. In the 5% cases needing intensive care, the disease development is gradual and takes nearly 9–10 days to progress from symptoms of upper respiratory tract infection (URTI) to ARDS. ARDS often is followed by uncorrectable hypotensive shock, multiorgan failure, and eventually death.
| Understanding Janapadoddhwamsa in Ayurveda and COVID-19 Pandemic|| |
As COVID-19 has developed itself into a pandemic, affecting a large population irrespective of their physical features, dietary patterns, psychological attributes, climate, etc., Ayurveda considers it as a Janapadoddhwansa., The concept of epidemic/pandemic is very well defined in Ayurveda under the heading of Janapadoddhwansa. In Ayurveda, the destruction of mass (Janapadoddhwansa) is said to be caused due to the degeneration (Dushti) of factors like Kala (time/season), Desha (region), Vayu (air), and Jala (water), which are common to all humans. The whole population gets Ksheena Bala (diminished body immunity) due to the consumption of polluted water, food, and air by which the virus enters the body to produce different symptoms. This is the reason why people with varied physical dispositions get afflicted with the same disease within the same timeframe.,
Acharya Sushruta, described the concept of pandemic/endemic in Ritucharya (seasonal regimen) as Maraka (lethal), where he explains how attacks (infections) of Rakshasa (viruses, bacteria) and Dushita (infected) air cause Janapadoddhwansa. Cause of Janapadoddhwansa are unsuitable season, wrong activities, curse of animals, demons (viruses, bacteria), disrespectful for nature and non-religious activities (killing and eating of innocent animals and birds) vitiates the environment affects nation by nation and produces breakdown of living culture produces endemic/pandemic disease. Infected people show symptoms of Kasa (coughing), Shwasa (breathlessness), Vamana (vomiting), Pratishyaya (running nose/rhinitis), Shirovedana (headache), and Jwara (fever); thus, various diseases and epidemics are manifested.
Janapadoddhwansa in Vasanta Ritu (season) results in incidence of Vata-Shlaishmika predominant Sannipaata Jwara (fever). The incidence of this Jwara points toward the rapid and violent vitiation of Vayu (air), Jala (water), Desha (ground) and Kala (time) due to the activities that can be assigned as Prajnaaparadha. Moreover, the predisposing factors such as old age and comorbidities like cardiovascular diseases, diabetes mellitus, respiratory diseases, hypertension, malignancies, etc., are causes of weakened Rogi Bala, which will result in fatality.
Krimi and the Novel Corona Virus
The concept of microorganisms has been well emphasized in Ayurveda in the context of Krimi, Bhoota, Graha, etc. The knowledge of three basic principles such as Hetu (cause), Linga (symptoms), and Aushadha (management) in Swastha and Atura is needed to treat any disease in Ayurveda. In the context of COVID-19, the cause of pandemic disease is a virus. Ayurveda classics like Charaka Samhita and Sushruta Samhita have described an infection almost like the novel coronavirus. The invisible Raktaja Krimi or Kaphaja Krimi is described as something that cannot be seen by the naked eye as they are Maha Sukshnma. It has a round shape, heavy with Roma (spikes) on them. Charaka Samhita description is so close to that of the novel coronavirus. Charaka explained how Kaphaja Krimi, after settling in the respiratory system, creates cough, severe congestion, and breathlessness and sometimes leads to death.,
These Raktaja Krimi cause Dushita Rakta, which in turn does Avarana (covering) of Vata leading to Vranashopha, to produce Santapa (burning sensations like fever), Atidourbalya (weakness), Aruchi (anorexia), Shiroruka (headache), and other symptoms as told in Charaka Samhita. In the context of coronavirus, Krimi (Raktaja Krimi) produces Rakthadusti by different Doshas to produce Raktavarana Vata Prakopa, leading to Vranashopha at Kantha Pradesha (viral pharyngitis); thus, there will be sore throat and throat congestion. If Krimi produces Vata-dominant Rakta Dusti, it shows Vataja symptoms like coughing, difficulty in breathing, sore throat, body ache, etc.; if Pitta-dominant Rakta Dusti occurs, it shows Pittaja symptoms like Jwara, Daha, Mukhapaka, etc. Similarly, if Kapha-dominant Rakta Dusti occurs, it shows Kaphaja symptoms like Pratishyaya, Gaurava, Tandra, Aalasya, throat congestion, etc. When these two or three Doshas are associated with each other, mixed symptoms will be produced according to the predominant Dosha involved. In the case of COVID-19, it occurs at throat as Pidaka. Probably initial Vatakaphaja symptoms will be predominant. Then it spreads to larynx (causes laryngitis), trachea (causes tracheitis), bronchus (causes bronchitis), and finally to alveoli (causes pneumonia) due to Parisarpana (AbhyantaraVisarpa/Vranashopha) nature of aggravation of Pitta in association with Rakta.
In COVID-19 infection, initially Vata-Kapha predominant symptoms produced, like low-grade fever (Manda Jwara), sneezing, and throat congestion. The infection then produced dry cough (suggesting involvement of Vata Dosha) and high-grade fever (Teevra jwara) (suggesting involvement of Pitta Dosha). Later on when there is involvement of alveoli, patient produces shortening of breath or breathlessness (Shwasa).
Bhootaabhishangaja Jwara and Symptoms of COVID-19
COVID-19 can be grouped under the class of Aagantuja Roga with special reference to the Bhootaabhishangaja Vikaara. In Bhootaabhishangaja Jwara, attack of Bhoota (bacteria, virus, other invisible microorganism, super natural power) happens first on the body and then aggravation of the three Doshas occurs. This Jwara is transmitted from one person to other person by close contact with infected persons, touching the air which passed from them, or air contaminated with Bhoota or poison (Visha). The management of Aagantuja disease should also follow the lines of Nija vikaara treatment. No disease can develop without involvement of Vata, Pitta, and Kapha. Identification of a suitable pathological model along with the associated features is very important. Charaka had been advised Vishghna medicine (anti-poisonous drugs) in the treatment of Bhootabhishangaja Jwara and also advised Dhoopa and Anjana in all types of Aagantuja Jwara, including Bhootaabhishangaja Jwara and when Jwara present only in skin.
Considering all the clinical features of COVID-19 and comparing with the clinical features mentioned in Ayurveda classics, COVID-19 can be considered as a Vata-Kaphaja Jwara of course, with some extent of Pitta involvement, in the beginning. But it obtains the status of a complete Sannipata jwara as disease progresses in certain groups of population. The clinical progression can be monitored as follows: symptomatic mild infection at presentation, leading to moderate disease to severe conditions, and then terminating in very fatal illness. Clinical features of Vata-Kaphaja Jwara and Sannipataja Jwara are as follows.
In Charaka Samhita,
Vata-Kapha Jwara: Sheeta, Gaurava, Tandra, Staimitya, Parvaruka, Shirograha, Pratishyaya, Kasa, Swedapravartam, Santapa, Madhyavega of Jwara.
Sannipata Jwara: Shwasa, Kasa, Pratishyaya, Mukhashosha, Atiparshvaruka
Samsannipata Jwara: Kanthah Shukairivavritah, Kasa Shwasa, Pratata Kanthakujanam
In Sushruta Samhita
Vata-Kapha Jwara: Staimitya, Parvabhrda, Nidra, Gaurava, Shirograha, Pratishyaya, Kasa, Swedapravartam, Santapa, Madhyavega of Jwar.
On other place also described Shoola, Kasa, Kaphotklesh, Sheeta, Vepathu, Peenasa, Gaurava, Aruchi, and Vistambha.
In Ashtanga Hridayam
Vata-Kapha Jwara: Tapahaani, Aruchi, Parvaruka, Shiroruka, Peenasa, Shwasa, Kasa, Vibandha, Sheeta, Jadyata, Timira, Bhrama, and Tandra.
Aaupsargika Disease of Ayurveda and Transmission of Infectious COVID-19
Healthy people can become infected with SARS-CoV-2 from already infected people and develop COVID-19 disease. The disease can spread in human being through small droplets from the nose or mouth which spread when a person with COVID-19 coughs or sneezes. These droplets land on objects and surfaces around the person. Other people can then be infected by touching those contaminated objects or surfaces, and then touching their eyes, nose, or mouth. People can also be infected if they breathe in droplets from a person with COVID-19 who coughs or sneezes in close proximity.,,,,,,
These types of disease are considered as Aaupsargika Roga (infectious disease) in Ayurveda. Sushruta had described that Jwara, Kushtha, Shosha, and Netra Abhishyanda is Aaupsargika disease and its infection is spread by direct contact with infected persons. Dalhana, the commentator of Sushruta Samhita, said that air escaped from the nose of these infected persons causes Shwasa (breathlessness), Kasa (cough), Pratishyaya (rhinitis), Twak Vikara (skin disease) Jwara (fever), Masurika (small/chicken pox), etc.Abhishangaja Jwara also transmitted from one person to other person by close contact with infected persons, touching the air which passed from them, or air contaminated with Bhoota or poison.
| ProbableAyurveda Samprapti (Pathogenesis) of COVID-19|| |
Virus enters the body through nasal passage, eye conjunctiva, or mouth mucosa, settles in Kantha Pradesha (pharynx) for some time, mixes with body mechanism by damaging the mucosa, and starts replications. After replication in large numbers, it shows their symptoms like pharyngitis, sore throat, sneezing, dry cough, and fever. Then it moves toward trachea, causes tracheitis, and causes bronchitis which causes excessive dry cough and shortening of breath. As disease progresses, it causes pneumonia and eventually multi-organ failure or death.
| Management Protocol of COVID-19 through Ayurveda|| |
The knowledge of Hetu (cause), Linga (symptoms), and Aushadha (management) in healthy and diseased persons are the three basic principles needed to treat any particular disease in Ayurveda. According to Ayurveda, the line of treatment should be planned to breakdown the aetiopathogenesis (Samprapti) of the disease. On the basis of the above-mentioned epidemiology, pathogenesis, and clinical features of COVID-19 disease, here, a rational and acceptable proposal for interventions of Ayurveda medicines and Panchakarma therapy is presented. Though, it is not limited to prophylaxis only, it is also effective for the therapeutic and an integrative management of COVID-19 disease. Here, we classified the different stages of contamination and immediacy with disease among individuals. Although till date no medical system has any specific treatment for COVID-19, clinical interventions are being done worldwide. Ayurveda mediations become more relevant by the fact that there is a vast explanation of causation and management of pandemic (Janapadoddhwansa) in Ayurveda.,
The line of treatment for COVID-19 is as follows:
Nidaana Parivarjana (moving to safe places or isolation or quarantine from infected persons/area)
To deactivate the viruses through antiviral medicines (no specific medicine yet developed)
To treat the symptoms of viral infections and complications on the basis of Doshika involvement.
To enhance the body immunity system and body strength of infected person.
Detoxification of body by Shodhana of aggravated Doshas by Panchakarma treatment
To protect the healthy persons from viral infection by increasing their immunity
The aims of Ayurveda are to preserve and retain the good health of healthy persons and to treat the diseased persons without any complications., In the context of pandemic COVID-19, it is very important to follow the aim of Ayurveda. So, we can divide the whole populations into three major groups: healthy population, infected population, and cured population from infection. These groups of population can also be categorized into subgroups on the basis of their exposure to viral infection and symptoms shown in their body [Table 1].
| Prophylaxis and Preventive Measures for Group I (Healthy Population) and Preventive Measures for Subgroups 1 and 2|| |
They should be in quarantine in their home and try not to expose to other persons of population. Follow the guidelines given by the local authorities and Government.
They should follow the Dinacharya and Ritucharya mentioned in different texts of Ayurveda.
Use of diets rich in Katu, Tikta, KashayaRasa (taste), fibres, and vitamin A, C, and E.
Drink adequate amount of lukewarm water whole day.
Regular practice of Yogasana, meditation, and Pranayama for at least 30 min and physical activity and exercise for healthy life-style
Adequate sleep of 7–8h in night; avoid daytime sleeping
Exposer of sunlight on whole body for 10–15 min daily.
Care for retainable and non-retainable urges; do not suppress the coming urges.
Avoidance of disease causing and aggravating factors (exposure to infection and excessive cold). Avoid air conditioning, cold water, cold drinks, fridge items.
Physical and social distancing for all groups must be necessary to avoid any viral contamination.
In addition to the above, the guidelines of Janpadoddwansha described in Ayurveda texts, needs to be followed:
Sthana Parityaga: return to home
Shanti Karma: work and maintain peace
Prayaschita: ready to pay penalty
Mangala: Being prosperous
Japa: keep mind Busy with chanting mantra and meditation
Homa: Fumigation, ritual habits which can disinfect air
Upahara: Gift rightly to right people
Iejya: sacrifices (Yagya karma)
Anjali Namaskar:- salute with both hand bind, avoid hand shake
Niyama: make and follow rules
Daya: kind toward living beings
Daana: give contribution to combat disease
Deeksha: provide knowledge to other persons
Devtabrahminguruparairbhavitavyam: pray together to god and elders
| Preventive Measures for Subgroups 3 and 4|| |
In addition to the above-mentioned preventive measures, subgroups 3 and 4 the below-mentioned measures needs to be followed,:
- Wash the hands regularly and thoroughly with an alcohol-based hand wash or disinfectant frequently for at least 20 seconds at a time with warm water and soap.
- When the hands are dirty, then avoid touching face, eyes, nose, or mouth
- Objects like phones, computers, utensils, dishware, and doorknobs disinfectants.
- Maintain at least 2 m (6 feet) distance between yourself and anyone who is coughing or sneezing.
- Make sure that the people around, follow good respiratory hygiene. It means covering mouth and nose with their bent elbow or tissue when they cough or sneeze. Then dispose the used tissue immediately.
- The Centres for Disease Control & Prevention (CDC) recommends placing the person in an airborne infection isolation room (AIIR) in addition to using standard precautions, contact precautions, and airborne precautions
- Respirator or facemask
- Medical gloves
- Eye protection
| Prophylaxis Measures for Groups 1 Medications|| |
Use of Rasayana as Immune Booster
Rasayana is the rejuvenative therapy used to boost the immune system of the body. Those Rasayana having the principal effects upon respiratory tract may be useful. Rasayana not only improves the immunity but also treats diseases at times. It may interrupt the course of disease and prevent from becoming a full-blown stage of the disease. It is already proved that fresh juice of Cynodon dactylon has immunomodulatory properties and DNA protective activities. Drugs like Amalaki, Haritaki, Guduchi, Ashwagandha, Garlic, etc. act as Rasayana and also cure diseases.Rasayana act as an antioxidant, anti-inflammatory, anti-stress, anti-microbial, and vaccine adjuvant, and provides immunity against diseases.,,,
Antioxidants and immunomodulators could help to prevent the occurrence of infectious diseases like swine flu; antioxidant supplement may be used in the management of swine flu and it may be taken as a preventive medicine throughout any infection phase. This theory can be adopted in the management of all types of endemic/pandemic diseases. There are a number of medicines in Ayurveda providing antioxidant properties.
Uses of Panchakarma therapy
Panchakarma is the natural detoxifying therapy comprising five purificatory measures. It has been scientifically proven that natural purificatory treatments can successfully eliminate toxins and infectious substances without damaging or causing any side effects. Charaka described that Panchakarma is the best treatment for Janpadodwansha.
Many Panchakarma procedures described in Dinacharya and Ritucharya as described in classics should be used by Group I populations. These are Anjana with Sauviranjana, Rasanjana, three types of herbal Dhoompana, Nasya with Anutail, Kaval Dharana, Taila Gandoosh, Murdhataila, Karnapurana, Abhayanga (Massage). In context of COVID-19, Seasonal Panchakarma like Vamana and Nasya karma in Vasanta Ritu (season) may provide effective prophylaxis by detoxifying the body.
- Nasya (nasal application): Use sesame oil/coconut oil/cow ghee in both the nostrils (Pratimarsh Nasya) in morning and evening.
- Gandoosha (oil pulling therapy): Fill the mouth with 1 table spoon sesame or coconut oil. Do not drink, swish in the mouth for 3 to 5 min and spit it out followed by warm water rinse. This can be done once or twice a day.
Uses of medicines:
- Drops (concentrated medicine/Bindu): Swarna-Bindu Prashana, Panchtulsi (Ocimum)
- Tablets (Vati): Guduchi Ghan vati, Mahasudarshan Ghan Vati, Panchnimbadi Vati
- Herbal powder (Choorna): Amalaki, Haritaki, Guduchi, Ashwagandha Garlic, Sitopladi choorna, Garlic (Allium sativum), Triphala Choorna, Panchkola, Turmeric (Curcuma longa) powder, Eranda Bhrista Haritaki Choorna, Carom or Ajwain (Trachyspermum ammi) seeds.
- Decoctions (Kashaya): Gojihwadi Kashaya, Kiratatiktadi Kashaya, Panchkola Kashaya, Dhanyaka-Shunthi Phant
- Avaleha:Chyavanprash, Brahma Rasayana, Amrit Bhallataka, Bhallatakavaleha, Vasavleha
- Bhashma/Pishti- Godanti Bhashma, Pravala pishti
- Fumigation (Dhoopana): Guggulu, Loban (Styrax benzoin) and Shallaki (Boswellia species)
- Drink herbal tea/decoction (Kashaya): made from Tulsi (Basil). Dalchini (Cinnamon). Kalimirch (Black pepper). Shunthi (Dry Ginger) and Munakka
- Spices: Haridra (tumteric), Jeera (cumin), Dhanyaka (coriander) and Lashuna (garlic) are recommenced in cooking.
- Golden milk: Half tea spoon Haridra (Turmeric) powder in 150ml hot milk, once or twice a day.
Curative and Preventive Measures of Group II (Infected Population)
The Ayurveda treatment not only helps to treat infection caused by a pathogen, but also rejuvenates the immune response, at different levels, to fight against invasions while strengthening the host to resist the virulence of infection. This group of individuals was treated according to their symptoms shown by dominating vitiated Doshas. In the context of COVID-19, primarily Vata and Kapha Dosha aggravated after that, as disease progresses, Pitta also involved showing high fever.
Subgroup I COVID-19-suspected cases showing no symptoms of infection (quarantined)
Subgroup I individuals do not have any clinical symptoms, but they are at high risk due to travel and contact history from pandemic COVID-19 areas. They require to be quarantined cautiously. This subgroup also requires Group I prophylaxis and preventive measures. In this subgroup, Deepana, Pachana, Rasayana (immune enhancing medicines), Vrishya and Jwaraghna, Kasahara, Shwasahara medicine should be practiced.
Tablets (Vati): Agnitundi vati, Chitrakadi vati, Vishtinduk Vati, Sanjivani Vati, and Tribhuvana Kirti Ras
Herbal powder (Choorna): Trikatu Choorna, Panchakola Choorna,
Decoction (Kashaya): Triphala, Vasa (Adhatoda vasica), Haridra (Curcuma longa), Tulsi (Ocimum sanctum), Madhuyasti (Glycyrrhiza glabra), Guduchi (Tinospora cordifolia), Shunthi (Zingiber officinale) and Haridra (Curcuma longa) Kalmegha (Andrographis paniculata), Kirattikta (Swertia chirata), Shigru (Moringa oleifera) can be used in pandemic COVID-19.
These medicines have broad-spectrum antivirals and protease inhibitors.,,
Drinking water: Shadanga Paneeya Kashaya for drinking whole day
Drink herbal tea/decoction (Kashaya): made from Tulsi (basil). Dalchini (cinnamon). Kalimirch (black pepper). Shunthi (dry ginger) and Munakka
Steam inhalation: with tulsi or haridra water, fresh pudina (mint) leaves or Ajwain (caraway seeds) should be used once in a day.
Gargling: water boiled with tulsi/Haridra/Triphala/Yashtimadhu/Saindhava salt
Dhoompanam: Prayogika Dhooma described by Charaka.
During dry cough/sore throat/throat irritation. Lavanga (Clove) powder mixed with natural sugar/honey can be taken 2–3 times a day
Subgroup II COVID-19-confirmed cases with mild COVID-19 symptoms (isolation ward)
Subgroup 2 individuals are positive to COVID-19 with clinical symptoms having mild fever, cold, dry cough, sneezing, etc. They should be shifted to isolation ward and carefully supervised for development of the COVID-19 disease, along with providing proper treatment to diminish the clinical symptoms by harmonizing the vitiated Dosha to control disease advancement. Those patients who are showing advancement of the disease may immediately require shifting to ICU.
Rasa Aushadi has better bioavailability and absorption through sublingual and oral route due to the nano size of their particles.,Swarna Bhasma mixed with black pepper powder and Ghrita had been found to get well absorbed through sublingual administration.
Sneezing, mild rhinitis (running nose) and mild cold: Haridrakhand, Lakshmivilas ras, Kaphketu Ras, Samshamani Vati, Guduchi Ghanavati, Vyoshadi Gutika, and Gojihvadi kashaya
Mild fever: Sanjivini Vati, Sudarshana Ghanavati, Naradiya Lakshmi Vilasa Rasa
Sore throat: chewing of Marichayadi vati, Lavangadi vati, Eladi vati, Yastimadhu vati, andVyaghri haritaki
Mild throat pain: Shotharilauha, Kanchanara Guggulu, Triphala Guggulu, and Arogyavardhini vati
Dry cough: Sitopaladi/Talisadi Choorna/Gutika, Kantakari Avaleha, Dashamool kashaya, and Yashtimadhu
Mild headache: Godanti Bhasm, Shirashooladi Vajra Ras, and Pathya shadandadi Kashaya
Nasya:Anutail, Shadabindu Tail, Till Tail, and Karanja Tail
Kavala:Nimba Patra Kalk
Gandoosha:Till Tail, Tilakalkodaka, and Milk
Dhoomapana:Vairechnika Dhooma, and Yava Choorna + Ghrita
Shiro Abhayanga:Brahmi Tail, Mahanarayana Tail
Subgroup III COVID-19-confirmed cases with moderate symptoms
Subgroup II individuals are positive to COVID-19 with moderate clinical symptoms having moderate grade fever, rhinitis (running nose, cold), excessive dry cough, shortening of breath, difficulty in respiration, Body ache, headache, etc. They should be shifted to isolation ward and may require tertiary care for progression of the COVID-19 disease. In this condition, conventional treatment should be used, and also patients may require ventilator. In this stage, we can also co-prescribed Ayurveda preparations to combat the effect of the pathology by balancing the vitiated Doshas.
Acute rhinitis (running nose): Nardiya Lakshmivilas ras, Kaphketu Ras, Samshamani Vati, Rambana Ras, Panchamrita Ras, Shleshmashlendra Ras, Abhrak Bhasma, Guduchi Ghanavati, Vyoshadi Gutika, Naga vati, Haridrakhand, Chitrak Haritaki, Gojihvadi kashaya, Bharangadi kashaya, and Vanphasadi Kashaya
Moderate fever: Sanjivini Vati, Tribhuvana kirti Rasa, Mrityunjaya Rasa, Hinguleshwar Rasa, Lakshmi narayana Rasa, Jwarakeshari Rasa, Sarvajwarhar lauha. Sudarshana Ghanavati
Moderate headache: Godanti Bhasm, Shirashooladi Vajra Ras, and Pathya shadandadi Kashaya
Severe sore throat: chewing of Marichayadi vati, Lavangadi vati, Eladi vati, Yastimadhu vati, Khadiradi vati, Vyaghri haritaki
Severe throat pain: Shothari lauha, Kanchanara Guggulu, Triphala Guggulu, Arogyavardhini vati, and Vishtinduk vati
Moderate coughing: Chandramrita Ras, Vasantmalti Ras, Sitopaladi Choorna, Talisadi Choorna/Gutika, Shringyadi Choorna, Tankana Bhasma, Dashamool kashaya, Yashtimadhu, Lavangadi vati, Khadiradi Vati, Vyaghri haritaki, Agastya Haritaki, Kantkaryavaleha, Kantkari Ghrita, Pippalyadi Ghrita, etc.
Shortness of breath: Shringa Bhasma, Shringadi Kashaya, Muktadi Choorna, Shatyadi Choorna, Shwasakuthar Ras, Kasturyadhi Gutika, Shwasananda Gutika, and Vasavleha
Muscle pain: MahaVatavidhvansana Ras, Vatari Guggulu, and Vishtinduk Vati
Nasya:Anutail, Shadbindu Tail, Pathadi Tail, Rasanjanadi Tail
Kavala:Matulung keshar + Saindhava + Trikatu
Dhoomapana:Prayogika Dhooma and Haridra+ Erandmoola+ Laksha+ Manahshila+ Devdaru + Jatamansi + Yava
Shirodhara:Brahmi Tail, Mahanarayana Tail
Vamana: Recommend Sadya Vamana
Abhyanga:Sarvanga Abhyanaga and Swedana
Subgroup IV COVID-19-confirmed cases with severe symptoms
Subgroup IV are positive to COVID-19 with severe clinical symptoms having high fever, severe cough with with expectoration, difficulty in respiration, severe body ache, severe headache, etc. They should be shifted to ICU ward and require tertiary care for progression of the COVID-19 disease. In this condition, conventional treatment must be used, and patients generally require ventilator. In this stage, we can also co-prescribed Ayurvedic preparations to subside the effect of the vitiated Doshas.
Acute rhinitis: Same as those medications in Sub group -III
High fever: Putapakva Vishama Jwarantak lauha, Sarvajwarhar lauha. Sanjivini Vati, Tribhuvana kirti Rasa, Mrityunjaya Rasa, Jwarakeshari Rasa, Jaya Mangala Rasa, Amar Sundari Vati, Lakshmi Narayana Rasa Sudarshana Ghanavati, Chausatha Prahara Pippali, Pippali rasayana,Laghu Vasant Malati, Panchatikta Kashaya, Guduchayadi Kashaya, Kiratatiktadi Kashaya
Chills: Vrihata vata chintamani Rasa, Vrihata Kasturi Bhairava Ras, Krishna Panchanana Rasa, SheetaBhanji Rasa, Sheetanshu Rasa, Mahajwarankusha Rasa, AYUSH-64, and Jwaramurari vati
Severe headache: Godanti Bhasm, Shirashooladi Vajra Ras, Chandra kant Rasa, Kamdugha Rasa, Pathya shadandadi Kashaya
Severe sore throat: chewing of Marichayadi vati, Lavangadi vati, Eladi vati, Yastimadhu vati, Vyaghri haritaki
Throat pain: along with those medicines mentioned in Subgroup III Brihata Vata Chintamni rasa
Severe coughing with expectoration: Kasa-Shwasa Chintamani Ras, Kaphachitamani Ras, Chandramrita Ras, Vasantmalti Ras, Talisadi Choorna/ Gutika, Shringyadi Choorna, Tankana Bhasma, Kantakari Avaleha, Vibhitakavleha, Vyaghri haritaki, Agastya Haritaki, Lavandi vati, Khadiradi Vati, Kantkari Ghrita, Pippalyadi Ghrita, etc.
Difficulty in breathing: Shwasa-kasa Chintamani Ras, Muktadi Choorna, Shwasakuthar Ras, Rasasindoor, Purna Chandrodaya Ras, Kasturyadi Gutika, Shwasananda Gutika, Siddha makardhvaja rasa
Severe muscle pain: Same as those medications prescribed in subgroup III
Anorexia: Agnitundi Vati, Chitrakadi vati, Hingwadi vati, Lavanabhaskar Chroorna, dadimashatak Choorna, Drakshavaleha, Draksharista, Tintidika Paanak
Nasya: Anutail, Karanja Tail
Kavala: Combination of Tripahla, Nagaramotha, Madhu, Tail
Gandoosha: Madhu, Sarpi, Kshara Jala
Dhoomapana: Vairechanika then Snaihika Dhooma, Manahshiladi Dhooma
Vamana: not recommend
Shirodhara: Brahmi Tail, Mahanarayana Tail
Abhyanga: Sarvanga Abhyanaga and Patrapinda Pottali Swedana
Subgroup V COVID-19-confirmed cases with critical illness and complications, patient on ventilator in ICU
Subgroup V individuals are positive to COVID-19 with critical clinical symptoms and complications having high fever, severe cough with expectoration, trouble breathing (breathlessness), repeated shaking with chills, loss of smell or taste, inability or confusion to arouse, persistent pain in the chest, bluish lips or face, excessive drowsiness and pneumonia (NCIP), etc. They must be shift in ICU ward and requires tertiary care for the COVID-19 disease. In this condition, conventional treatment must be used and patients generally require ventilator. In this stage, we can also co-prescribe Ayurveda preparations to subside the effect of the vitiated Doshas.
High fever: Same medications as described in subgroup 4 can be used
Severe throat pain: Same medications as described in subgroup 4 can be used
Severe coughing with expectoration: Same medications as described in subgroup 4 can be used
Difficult breathing (breathlessness): Shwasa-kasa Chintamani Ras, Brihada Shwasa Chintamani Ras, Nagavallabh Ras, Brihada Kasturi Bharava Ras, Suryavarta Ras, Shringa Bhasma, Mukta Bhasma, Muktadi Choorna, Shwasakuthar Ras, Rasasindoor, Purna Chandrodaya Ras, Kasturyadi Gutika, Shwasananda Gutika, Siddha Makardhvaja rasa, Soma choorna, Vijaya vati, Vyaghri haritaki, Agastya Haritaki, Bharngi Guda, Kanakasava, Vasarista, Vasa Ghrita, Manahshiladi Ghrita, Shringadi Ghrita, Shataputi Abhraka bhasma, Rasamanikya, Gold Bhasma, Shwasananda Gutika, Sameera Pannaga Rasa
Pneumonia and persistent pain or pressure in the chest: Shwasa Kasa Chinthamani Rasa, Vrihata vata chintamani Rasa, Chaturbhuja Rasa, Trailokya Chintamani Rasa, Hemagarbha Pottali Rasa. Shataputi Abhraka bhasma, Karpooradi Choorna, Chausatha Prahara Pippali, Suvarna Malini Vasanta Rasa
Repeated shaking with chills: Vrihata vata chintamani Rasa, Vrihata Kasturi Bharava Ras, Vatakulantak Rasa, Murchchhantak Rasa, Swarnamakshika Bhasma, Siddha makardhvaja rasa, Krishna Chaturmukha Rasa, Panchanana Rasa, SheetaBhanji Rasa, Sheetanshu Rasa, Mahajwarankusha Rasa, AYUSH-64, Jwaramurari vati
Confusion or inability to arouse: Yogendra Rasa, Chandeshwar Rasa, Brahmi Vati, Smriti Sagar Rasa, Vatakulantak Rasa, Saraswatarista, Jatamansi Choorna/Kashaya
Anorexia: Yavanishadava Choorna, Hingwastak Chroona, Lavangadi Choorna, Karpooradi Choorna, Karavyadi Gutika, Sutashekhar Rasa, Aadrarakavaleha, Panchasava, Saptarisita, Jirakadi Ghrita
Bluish lips or face: use ventilator
Not recommend as in emergency condition.
| Conclusion|| |
Ayurveda has mentioned Janpadoddhwansa, a number of invisible and very minute objects like Krimi, Bhoota, etc. that cause serious diseases, different types of Aagantuja Vikara (including unknown causes), and different kinds of Aupasargika Vyadhi. The conclusion drawn from above-mentioned interpretations, it is clear that COVID-19 is Aupasargika, and Janpadoddhwansa Vyadhi caused by a type of Krimi or Bhoota (SARS-CoV-2) which comes from outside of the body. The clinical symptoms of COVID-19 resemblances with Abhishangaja Jwara, Vata-Kaphaja Jwara and Sannipataja Jwara and management are proposed symptomatically.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
Christou L. The global burden of bacterial and viral zoonotic infections. Clin Microbiol Infect 2011;17:326-30.
Cascio A, Bosilkovski M, Rodriguez-Morales AJ, Pappas G. The socio-ecology of zoonotic infections. Clin Microbiol Infect 2011;17:336-42.
Grais RF, Strebel P, Mala P, Watson J, Nandy R, Gayer M. Measles vaccination in humanitarian emergencies: A review of recent practice. Confl Health 2011;5:21.
Sheu TG, Deyde VM, Okomo-Adhiambo M, Garten RJ, Xu X, Bright RA, et al
. Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008. Antimicrob Agents Chemother 2008;52:3284-92.
Geretti AM, Armenia D, Ceccherini-Silberstein F. Emerging patterns and implications of HIV-1 integrase inhibitor resistance. Curr Opin Infect Dis 2012;25:677-86.
Locarnini SA, Yuen L. Molecular genesis of drug-resistant and vaccine-escape HBV mutants. Antivir Ther 2010;15:451-61.
Wyles DL. Antiviral resistance and the future landscape of hepatitis C virus infection therapy. J Infect Dis 2013;207(Suppl 1):S33-9.
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al
. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet2020;395:497-506.
van der Hoek L. Human coronaviruses: What do they cause? Antivir Ther 2007;12:651-8.
Geller C, Varbanov M, Duval RE. Human coronaviruses: Insights into environmental resistance and its influence on the development of new antiseptic strategies. Viruses 2012;4:3044-68.
World Health Organization: novel-coronavirus-2019; Available at: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance [Last accessed on 2020 April 28].
World Health Organization Novel Coronavirus (2019-nCoV).Available at https://www.who.int/emergencies/diseases/ novel-coronavirus-2019. [Last accessed on 2020 April 28].
World Health Organization; novel-coronavirus-2019 (2019-nCoV) Situation Report. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports/ [Last accessed on 2020 April 28].
Wu Y-C, Chen C-S, Chan Y-J. The outbreak of COVID-19: An overview. J Chinese Med Assoc 2020;83 (3:217-20 doi: 10.1097/JCMA.0000000000000270
Perlman S. Another decade, another coronavirus. N Engl J Med2020;382:760-2.
Peiris JS, Chu CM, Cheng VC, Chan KS, Hung IF, Poon LL, et al
; HKU/UCH SARS Study Group. Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: A prospective study. Lancet 2003;361:1767-72.
Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus AD, Fouchier RA. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med 2012;367:1814-20.
Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al
. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 2020 doi: 10.1056/NEJMoa2001017
Chan Jasper FW, Yuan S, Kok KH, To Kelvin KW, Chu H, Yang J, et al
. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: A study of a family cluster. Lancet 2020 doi:10.1016/S0140-6736(20)30154–9
Holshue ML, DeBolt C, Lindquist S, Lofy KH, Wiesman J, Bruce H, et al
. First case of 2019 novel coronavirus in the United States. N Engl J Med 2020 doi: 10.1056/NEJMoa2001191
Rothe C, Schunk M, Sothmann P, Bretzel G, Froeschl G, Wallrauch C, et al
. Transmission of 2019-ncov infection from an asymptomatic contact in Germany. N Engl J Med 2020;382:970-1.
Pgab LT, Nguyen TV, Luong QC, Nguyen TV, Nguyen HY, Le HQ, et al
. Importation and human-to-human transmission of a novel coronavirus in Vietnam. N Engl J Med 2020. doi:10.1056/NEJMc2001272
Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al
. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study. N Engl J Med 2020. doi:10.1016/S0140-6736(20)30211–7
Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al
. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med 2020. doi:10.1056/NEJMoa200131
Wang W, Tang J, Wei F. Updated understanding of the outbreak of 2019 novel coronavirus (2019-nCoV) in Wuhan, China. J Med Virol 2020. doi:10.1002/jmv.25689
The Centers for Disease Control and Prevention (CDC- USA).Available at: https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/index.html. [Last accessed on 2020 April 28].
WHO Coronavirus disease 2019 (COVID-19) situation report—43. Available at: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200303-sitrep-43-covid-19.pdf?sfvrsn=76e425ed_2. [Last accessed on 2020 April 28].
Zhou F, Yu T, Du R, Fan G, Liu Y, et al
. Clinical course and risk factors for mortality of adult inpatients with covid-19 in Wuhan, China: A retrospective cohort study. Lancet2020. doi:10.1016/S0140-6736(1020)30566-30563
Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (covid-19) outbreak in China: Summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention. JAMA 2020;323:1239-42. doi:1210.1001/jama.2020.2648
Jyotirmoy S, Rekha SD. Concept of epidemic diseases in ayurveda. IJHRMLP 2016;2:24-8.
Xu B, Gutierrez B, Mekaru S, Sewalk K, Goodwin L, Loskill A, et al
. Epidememiological data from the covid-19 outbreak, real-time case information. Sci Data 2020;7:106. doi:10.1038/s41597-41020-40448-41590
Agnivesha Charaka. Dridhabala, Charaka Samhita, Vimanasthana, Janpadoddhwansneeya Vimanadhyaya
, with ‘Charaka Chandrika’ Hindi commentary, Brahmanand Tripathi. Vol. 1. Chaukhabha Surbharati Prakashan, Varanasi,2006. p.677-9.
Sushruta Nagarjuna , Sushruta Samhita, Sutra Sthana, Ritucharya Adhayayam with “Ayurveda Tatvadipika”, Hindi commentary, Ambikadatta Shastri. Vol. 1. Chaukhambha Sanskrit Sansthan, Varanasi, 2009; p. 29-30.
Wu C, Chen X, Cai Y, Xia J, Zhou X, et al
. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Int Med 2020; doi:10.1001/jamainternmed.2020.0994
Agnivesha Charaka. Dridhabala, Charaka Samhita, Sutrasthana, Dirghanjeeviteeya adhyayam
, with ‘Charaka Chandrika’ Hindi commentary, Brahmanand Tripathi. Vol 1. Chaukhabha Surbharati Prakashan, Varanasi; 2006. Vol-1, 1/24, p.09.
Agnivesha . Charaka, Dridhabala, Charaka Samhita, Vimanasthana, Vyadhitaroopeeya Vimanadhyaya, with ‘Charaka Chandrika’ Hindi commentary, Brahmanand Tripathi. Vol 1. Chaukhabha Surbharati Prakashan, Varanasi;2006. p.712-3.
Sushruta Nagarjuna . Sushruta Samhita, Uttaratantra, Krimiroga Pratishedha Adhayayam with “Ayurveda Tatvadipika”, Hindi commentary, Ambikadatta Shastri. Vol 2. Chaukhambha Sanskrit Sansthan, Varanasi;2008. p. 400-1.
Vagbhata, Astanga Hridayam, Nidanasthana; Vatashonita nidanam with ‘Vidyotini’ Hindi commentary by Kaviraj Atrideva Gupta, Chaukhamba Prakashan, Varanasi; 2009. 16/33–34, p.384.
Agnivesha . Charaka, Dridhabala, Charaka Samhita, Sutrasthana, Dirghanjeeviteeya adhyayam, with ‘Charaka Chandrika’ Hindi commentary, Brahmanand Tripathi, Vol. 1. Chaukhabha Surbharati Prakashan, Varanasi;2006. p.373.
Agnivesha . Charaka, Dridhabala, Charaka Samhita, Chikitsasthana, Jwarachikitsa adhyayam, with ‘‘Vidyotini’ Hindi commentary, Kashinatha Shastri, Chaukhabha Bharati Academy, Varanasi, 2007; Vol-2, 3/114–118, p.124-5.
Sushruta, Nagarjuna, Sushruta Samhita, Sutra Sthana, Aaturopkramaneeya Adhayayam with “Ayurveda Tatvadipika”, Hindi commentary, Ambikadatta Shastri, Chaukhambha Sanskrit Sansthan, Varanasi;2009; Vol-1; 35/23;p.171.
Agnivesha , Charaka, Dridhabala, Charaka Samhita, Chikitsasthana, Jwarachikitsa adhyayam, with ‘‘Vidyotini’ Hindi commentary, Kashinatha Shastri, Chaukhabha Bharati Academy, Varanasi, 2007; Vol-2; 3/176–177, p.144.
Vagbhata , Astanga Hridayam, Nidanasthana; Jwaranidanam with ‘Vidyotini’ Hindi commentary by Kaviraj Atrideva Gupta, Chaukhamba Prakashan, Varanasi, 2009; 2/25, p.300.
Vagbhata , Astanga Hridayam, Chikitsasthana; Jwarachikitsitam with ‘Vidyotini’ Hindi commentary by Kaviraj Atrideva Gupta, Chaukhamba Prakashan, Varanasi, 2009; 1/16–17, p.390.
Agnivesha , Charaka, Dridhabala, Charaka Samhita, Chikitsasthana, Jwarachikitsa adhyayam, with ‘‘Vidyotini’ Hindi commentary, Kashinatha Shastri, Chaukhabha Bharati Academy, Varanasi, 2007; Vol-2, 3/103–109, p.120-1.
Agnivesha , Charaka, Dridhabala, Charaka Samhita, Chikitsasthana, Jwarachikitsa adhyayam, with ‘‘Vidyotini’ Hindi commentary, Kashinatha Shastri,Chaukhabha Bharati Academy, Varanasi, 2007; Vol-2, 3/86, p.117.
Agnivesha , Charaka, Dridhabala, Charaka Samhita, Chikitsasthana, Jwarachikitsa adhyayam, with ‘‘Vidyotini’ Hindi commentary, Kashinatha Shastri, Chaukhabha Bharati Academy, Varanasi, 2007; Vol-2, 3/101, p.120.
Sushruta , Nagarjuna, Sushruta Samhita, Uttaratantra, Krimiroga Pratishedha Adhayayam with “Ayurveda Tatvadipika”, Hindi commentary, Ambikadatta Shastri, Chaukhambha Sanskrit Sansthan, Varanasi,;2008; Vol-2; 39/48,49,50(2); p.175.
Sushruta Nagarjuna, Sushruta Samhita, Nidanasthana, Kushtha Nidana Adhayayam with “Ayurveda Tatvadipika”, Hindi commentary, Ambikadatta Shastri, Chaukhambha Sanskrit Sansthan, Varanasi,;2009; Vol-1; 5/32–33; p.325.
Rastogi S, Pandey DN, Singh RH, COVID-19 pandemic: A pragmatic plan for Ayurveda intervention. J Ayurveda Integr Med doi:10.1016/j.jaim.2020.04.002
Agnivesha , Charaka, Dridhabala, Charaka Samhita, Sutrasthana, Arthedashamahamuleeya adhyayam, with ‘Charaka Chandrika’ Hindi commentary, Brahmanand Tripathi, Chaukhabha Surbharati Prakashan, Varanasi, 2006; Vol-1, 30/26, p.565.
Agnivesha , Charaka, Dridhabala, Charaka Samhita, Nidanasthana, Apasmara Nidana adhyayam, with ‘Charaka Chandrika’ Hindi commentary, Brahmanand Tripathi, Chaukhabha Surbharati Prakashan, Varanasi, 2006; Vol-1, 8/23, p.651.
Agnivesha , Charaka, Dridhabala, Charaka Samhita, Sutrasthana, Snehadhyayam, with ‘Charaka Chandrika’ Hindi commentary, Brahmanand Tripathi, Chaukhabha Surbharati Prakashan, Varanasi, 2006; Vol-1, 13/62–64, p.277.
Sushruta , Nagarjuna, Sushruta Samhita, Sutra Sthana, Ritucharya Adhayayam with “Ayurveda Tatvadipika”, Hindi commentary, Ambikadatta Shastri, Chaukhambha Sanskrit Sansthan, Varanasi,;2009; Vol-1; 6/22; p.29-30.
Agnivesha , Charaka, Dridhabala, Charaka Samhita, Vimanasthana, Janpadoddhwansneeya Vimanadhyaya
, with ‘Charaka Chandrika’ Hindi commentary, Brahmanand Tripathi, Chaukhabha Surbharati Prakashan, Varanasi, 2006; Vol-1, 3/14–18; p.679.
Pramod Malik, Geeta Rani. ‘Covid-19 Effect Various Country Economic’.Int J Curr Adv Res 2020;09:21643-5. doi:10.24327/ ijcar.2020.21645.4258
Bhinde Sagar, Rasayana: A better alternative for desire. J Ayurveda Holistic Med 2013;1:6-14.
Rekha PS, Kuttan G, Kuttan R. Antioxidant activity of brahma rasayana. Indian J Exp Biol 2001;39:447-52.
Patwardhan B, Chavan-Gautam P, Gautam M, Tillu G, Chopra A, Gairola S, et al
. Ayurveda rasayana in prophylaxis of covid-19. Curr Sci 2020, https://www.currentscience.ac.in/php/forthcoming/2020/COVID-2019.pdf.
Patwardhan B, Tillu G. Universal health coverage and AYUSH systems. J Ayurveda Integr Med 2018;9:1-2 https://doi.org/10.1016/j.jaim.2018.1003.1001.
Tillu G. Ayush research for new India: Vision and strategies. J Ayurveda Integr Med 2018;9:240-4. https://doi.org/210.1016/j.jaim.2018.1006.1001.
Howard Friel. HarveyLederman; A nutritional supplement formula for influenza A (H5N1) infection in humans. Medical Hypothesis 2006;67:578-87. https://doi.org/10.1016/j.mehy.2006.02.040
Agnivesha , Charaka, Dridhabala, Charaka Samhita, Vimanasthana, Janpadoddhwansneeya Vimanadhyaya
, with ‘Charaka Chandrika’ Hindi commentary, Brahmanand Tripathi, Chaukhabha Surbharati Prakashan, Varanasi, 2006; Vol-1, 3/12–13; p.679.
Agnivesha , Charaka, Dridhabala, Charaka Samhita,
Sutrasthana, Matrashiteeya adhyayam, with ‘Charaka Chandrika’ Hindi commentary, Brahmanand Tripathi, Chaukhabha Surbharati Prakashan, Varanasi, 2006; Vol-1, 5/15–92; p.115-36.
Agnivesha , Charaka, Dridhabala, Charaka Samhita,
Sutrasthana, Tasyashiteeya adhyayam, with ‘Charaka Chandrika’ Hindi commentary, Brahmanand Tripathi, Chaukhabha Surbharati Prakashan, Varanasi, 2006; Vol-1, 6/22–26; p.153.
Ministry of AYUSH. Govt. of India, Ayurveda’s immunity boosting measures for self care during COVID 19 crisis. Available at: https://www.mohfw.gov.in/pdf/ImmunityBoostingAYUSHAdvisory.pdf. [Last accessed on 2020 April 28].
Rege AA, Chowdhary AS. Evaluation of some medicinal plants as putative HIV-protease inhibitors. Indian Drugs 2013;50:24-8.
Panche AN, Chandra S, Diwan AD. Multi-target β-protease inhibitors from Andrographis paniculata
: In Silico and in vitro studies. Plants (Basel) 2019;8:231. Published 2019 Jul 17. doi:10.3390/plants8070231.
Rege A, Sadashiv Chowdhary A. Evaluation of ocimum sanctum and tinospora cordifolia as probable HIV-protease inhibitors. Intl J Pharm Sci Rev Res 2014;25:315-8.
Sharma R, Prajapati PK. Nanotechnology in medicine: Leads from Ayurveda. J Pharm Bioallied Sci 2016;8:80-1. doi:10.4103/0975-7406.171730.
Panigrahi HK. Efficacy of ayurvedic medicine in the treatment of uncomplicated chronic sinusitis. Anc Sci Life 2006;26:6-11.
Patil-Bhole T, Patil S, Wele AA. Assessment of bioavailability of gold bhasma in human participants—A pilot study. J Ayurveda Integr Med 2018;9:294-7. doi:10.1016/j.jaim.2018.1004.1002